🇺🇸 FDA
Patent

US 11672794

Therapeutic targeting of the BAP1 complex in cancer

granted A61KA61K31/423A61K31/473

Quick answer

US patent 11672794 (Therapeutic targeting of the BAP1 complex in cancer) held by Northwestern University expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Northwestern University
Grant date
Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/423, A61K31/473, A61P, A61P35/02